Aclaris Therapeutics Inc (FRA:8AT)
€ 0.9182 -0.0174 (-1.86%) Market Cap: 66.10 Mil Enterprise Value: -42.89 Mil PE Ratio: 0 PB Ratio: 0.51 GF Score: 50/100

Q1 2023 Aclaris Therapeutics Inc Earnings Call Transcript

May 08, 2023 / 12:00PM GMT
Release Date Price: €11.85
Operator

Good day, and thank you for standing by. Welcome to Aclaris Therapeutics First Quarter 2023 Conference Call. (Operator Instructions)

Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Robert Doody, Head of Investor Relations. Please go ahead.

Robert A. Doody
Aclaris Therapeutics, Inc. - VP of IR

Thank you. I am Robert Doody, Head of Investor Relations for Aclaris. Please note that earlier today, we issued a press release highlighting our first quarter 2023 financial results and other business matters. For those of you who have not yet seen it, you will find the press release posted under the Press Releases page of the Investors section of our website, www.aclaristx.com.

In addition, we will be referring to a slide deck entitled Q1 2023 Investor Conference Call, which can be found on the Investor page of our corporate website and furnished as an exhibit to our Form 8-K that we filed with the SEC

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot